Please login to the form below

Not currently logged in

Nycomed results hit by patent issues

Nycomed 2010 figures hit by patent losses, but company says it is in a good position to benefit from pharma trends

Nycomed, the Switzerland-based pharmaceutical company, has posted a 21 per cent decline in earnings before interest, taxes, depreciation and amortisation, with the figure falling to €850.5m for 2010.

The company's net turnover decreased by 1.8 per cent to €3.2bn in 2010, due to declining sales of pantoprazole following the loss of patent exclusivity in several markets and the full-year impact of the expiry of the pantoprazole patent in other key European markets.

Håkan Björklund, CEO of Nycomed, said: "Our performance in 2010 demonstrates that Nycomed is well positioned to gain from major trends in the pharmaceutical industry. We are already generating impressive sales and continuing to expand in emerging markets, which will be a powerful engine of growth for the future."

Nycomed reported that its turnover in emerging markets rose by 30 per cent in 2010. Russia/CIS is its largest market, while Brazil has moved into the second place. The company also made an acquisition in China and launched a number of affiliates in Asia, Latin America and the Middle East.

European sales of the company's leading product, pantoprazole, stabilised following widespread patent expiries, it reported. Its portfolio of established and innovative medicines grew strongly, with particularly good performances from Actovegin, TachoSil, Instanyl and Calcichew.

The company said its 2011 performance would be hit by continuing strong marketing and sales efforts around launches of Daxas, the drug to combat chronic obstructive pulmonary disease, which received EU marketing authorisation in July 2010.

3rd March 2011


Featured jobs

Subscribe to our email news alerts


Add my company

Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...